{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellectra+2000", "query": { "intervention": "Cellectra 2000" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellectra+2000&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:47:35.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02172911", "title": "A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "INO-3112", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™-5P", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2014-06-06", "completion_date": "2017-09-07", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 3, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02172911" }, { "nct_id": "NCT02514213", "title": "Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "2mg INO-5150 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "8.5mg INO-5150 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "Electroporation using CELLECTRA®-5P", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 62, "start_date": "2015-07", "completion_date": "2017-12-12", "has_results": false, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 10, "location_summary": "Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska + 7 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02514213" }, { "nct_id": "NCT05293249", "title": "dMAbs for Prevention of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "dMAb AZD5396", "type": "COMBINATION_PRODUCT" }, { "name": "dMAb AZD8076", "type": "COMBINATION_PRODUCT" }, { "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device", "type": "COMBINATION_PRODUCT" }, { "name": "Hylenex", "type": "DRUG" }, { "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Pablo Tebas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 61, "start_date": "2022-05-19", "completion_date": "2025-11-21", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293249" }, { "nct_id": "NCT01142362", "title": "Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "VGX-3400X", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 32, "start_date": "2010-06", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2017-09-13", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 2, "location_summary": "Overland Park, Kansas • Rockville, Maryland", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142362" }, { "nct_id": "NCT03721978", "title": "REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Dysplasia", "Cervical High Grade Squamous Intraepithelial Lesion", "HSIL" ], "interventions": [ { "name": "VGX-3100", "type": "BIOLOGICAL" }, { "name": "Matched Placebo", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™-5PSP", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 203, "start_date": "2019-02-28", "completion_date": "2022-09-15", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 27, "location_summary": "Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721978" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT04001413", "title": "Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Oropharynx Cancer", "HPV-Related Carcinoma" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-09-17", "completion_date": "2021-03-25", "has_results": false, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001413" }, { "nct_id": "NCT01260727", "title": "Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PENNVAX-G DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo PENNVAX-G Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo MVA-CMDR Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 92, "start_date": "2010-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01260727" }, { "nct_id": "NCT01304524", "title": "A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Intraepithelial Neoplasia" ], "interventions": [ { "name": "VGX 3100", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™-5P", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 167, "start_date": "2011-04", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Colton", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01304524" }, { "nct_id": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Human Papilloma Virus" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "CELLECTRA®5P device", "type": "DEVICE" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2017-06-26", "completion_date": "2021-03-19", "has_results": true, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-09-02T21:47:35.337Z", "location_count": 14, "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162224" } ] }